Reactions 1680, p270 - 2 Dec 2017 Acquired resistance to osimertinib: case report In a study of 86 patients, a patient [age and sex not stated] was described, who acquired resistance to osimertinib during treatment of a non-small-cell lung carcinoma [route, dosage and duration of treatment to reaction onset not stated]. The patient, who had T790M-positive non-small-cell lung carcinoma, started receiving treatment with osimertinib. Subsequently, a serial plasma genotyping confirmed the acquired KRAS Q61K mutation on osimertinib therapy [outcome not stated]. Author comment: "The remaining 11 [patients] had loss of T790M, of whom 5 had evidence of a competing resistance mechanism: 2 with histologic transformation to SCLC, one with BRAF V600E, one with an FGFR3-TACC fusion, and one with KRAS Q61K." "For the final case, we confirmed the acquired KRAS Q61K on therapy using serial plasma genotyping." Oxnard GR, et al. Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC. Cancer Research 77 (Suppl. 1): abstr. 4112, No. 13, Jul 2017. Available from: URL: http:// doi.org/10.1158/1538-7445.AM2017-4112 [abstract] - USA 803284799 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680
Reactions Weekly – Springer Journals
Published: Dec 2, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud